Pliant stock rises as lung disease drug bexotegrast meets main goal of trial
Designer491/iStock via Getty Images gentle treatment (Nasdaq: PLRX) said that the bexotegrast 320 mg dose met the primary and secondary goals of a Phase 2a trial in patients with some form of lung disease. The company reports 24 weeks…
